Client News

HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX 0215

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

InflaRx to Present at the BTIG Virtual Biotechnology Conference

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

InflaRx Reports Second Quarter 2021 Financial & Operating Results

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

Abivax announces the pricing of its oversubscribed capital increase of EUR 60M and convertible bonds of EUR 25M, totaling EUR 85M new financing

XPhyto signs transformative acquisition agreement with 3a-diagnostics, to enter hi-tech biosensor market and expand its diagnostic product portfolio

es Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib